Navigation Links
Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
Date:12/10/2012

SEATTLE Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy, or FSHD, by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease. The protein activity is what damages muscle cells and leads to progressive muscle weakness and atrophy in FSHD patients.

The genetic and disease mechanisms of FSHD were discovered by an international team of scientists led by Stephen Tapscott, M.D., Ph.D., a member of the Fred Hutch Human Biology Division, in a series of studies published between 2010 and early 2012. Tapscott will lead the Fred Hutch work in the GSK collaboration.

The team's discoveries also have implications for developing cancer immunotherapies because researchers also discovered that DUX4 regulates cancer/testis antigens. Cancer/testis antigens are encoded by genes that are normally expressed only in the human germ line but are also abnormally expressed in various tumor types, including melanoma and carcinomas of the bladder, lung and liver. This knowledge will give researchers a way to manipulate the expression of cancer/testis antigens, potentially opening the opportunity to use these antigens in a cancer vaccine.

The partnership with GSK is a first of its kind for Fred Hutch, which is also the first U.S.-based institution to sign on with GSK's "Discovery Partnership with Academia" (DPAc) program. GSK launched the program last year to combine the insight and creativity of the academic world with GSK's drug-discovery expertise to turn innovative research into medicines that benefit patients.

GSK currently has DPAc collaborations in place with Cambridge University and the University of Dundee in the U.K.

Unlike traditional licensing agreements in which the licensee is given full control to develop a discovery, the collaboration will involve GSK and Fred Hutch scientists working together to develop, test and hopefully bring to market a clinical treatment.

"GSK has huge expertise in developing agents against protein activity, so our opportunity to work with them is fantastic," Tapscott said.

"At GSK we believe that combining our drug-discovery expertise with the in-depth disease knowledge of specialist academic groups can seed innovation and help speed up the discovery and development of new medicines," said Pearl Huang, global head of DPAc. "We're excited to be expanding our academic program in North America and are looking forward to working closely with scientists like Dr. Tapscott, whose deep understanding of disease biology will complement our own work in this field."

FSHD affects about one in 20,000 individuals and usually begins in late adolescence. The effects start around the facial and upper-extremity muscles and eventually progress to muscles in the lower extremity. People with more severe FSHD become wheelchair bound and their life spans are often shortened.

In an era of flat federal research funding, this collaboration signals an increasing interest on the part of Fred Hutch to develop partnerships that further its lifesaving and innovative research.

"We're looking for more creative academic-industry partnerships like this one between Fred Hutch and GSK," said Ulrich Mueller, vice president of industry relations and technology transfer at Fred Hutch.

Tapscott's research on FSHD, which provides the scientific basis for the collaboration with GSK, was funded by Friends of FSH Research, the National Institute of Neurological Disorders and Stroke, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Financial terms of the Fred Hutch-GSK partnership were not disclosed.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related biology news :

1. Stem cell research provides hope for infertile cancer survivors
2. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
3. Clinical trial tests rice bran to prevent cancer
4. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
5. Predicting the age at menopause of women having suffered from childhood cancers
6. Research shows immune system response is detrimental to novel brain cancer therapy
7. University of Tennessee researchers find fungus has cancer-fighting power
8. Newly discovered effects of vitamin D on cancer
9. Fruit fly studies guide investigators to misregulated mechanism in human cancers
10. Does your job increase your breast cancer risk?
11. Reconsidering cancers bad guy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
(Date:6/22/2016)... Philadelphia, PA (PRWEB) , ... June 22, 2016 ... ... the University City Science Center’s Port business incubator and current participant in the ... therapy and treatment for cancer patients. , Quantitative Radiology Solutions helps physicians ...
Breaking Biology Technology: